"Stress-alleviating" and "vigilance-enhancing" actions of Ginkgo biloba extract (EGb 761)

Drug Development Research

Volumn 62, Issue 1, 2004, Pages 1-25

  DeFeudis, Francis V ^a   Drieu, Katy ^b  

^a Institute for BioScience   (United States)

^b IPSEN   (France)

Author keywords

Ageing; Dementia; Ginkgo biloba; Glucocorticoids; Stress hormones; Vigilance

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE RECEPTOR; BILOBALIDE; BUSPIRONE; CARBAMAZEPINE; CATECHOLAMINE; CHOLINESTERASE INHIBITOR; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DIAZEPAM; DONEPEZIL; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GLUCOCORTICOID RECEPTOR; GLUCOSE; NEUROLEPTIC AGENT; NORADRENALIN; PREDNISOLONE; RIVASTIGMINE; SEROTONIN; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VALPROIC ACID;

ADAPTATION; ADRENAL CORTEX; AGGRESSION; ALERTNESS; ANIMAL BEHAVIOR; ANXIETY DISORDER; BRAIN FUNCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITION; DEMENTIA; DEPRESSION; DIZZINESS; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; ELECTROENCEPHALOGRAPHY; ENERGY METABOLISM; HEADACHE; HIPPOCAMPUS; HUMAN; MAZE TEST; NONHUMAN; PSYCHOMETRY; RECEPTOR DOWN REGULATION; REVIEW; SLEEP TIME; STRESS; TINNITUS;

EID: 7644229150     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10351     Document Type: Review

References (122)

1. Ahmann P, Waltonen S, Olson K, Theye F, Van Erem A, LaPlant R. 1993. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 91:1101-1106.
2. Allain H, Raoul P, Lieury A, LeCoz F, Gandon JM, d'Arbigny P. 1993. Effect of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther 15:549-558.
3. Allard M. 1986. Traitement des troubles du vieillissement et extrait de Ginkgo biloba. De la pharmacologie à la clinique. Presse Med 15:1540-1545.
4. Amri H, Ogwuegbu SO, Boujrad N, Drieu K, Papadopoulos V. 1996. In vivo regulation of the peripheral-type benzodiazepine receptor and glucocorticoid synthesis by the Ginkgo biloba extract EGb 761 and isolated ginkgolides. Endocrinology 137:5707-5718.
5. Amri H, Drieu K, Papadopoulos V. 1997. Ex vivo regulation of adrenal cortical cell steroid and protein synthesis, in response to adrenocorticotropic hormone stimulation, by the Ginkgo biloba extract EGb 761 and isolated ginkgolide B. Endocrinology 138:5415-5426.
6. Anonymous. 1996. Behavioral and psychological signs and symptoms of dementia: Implications for research and treatment. Proceedings of an international consensus conference. Lansdowne, Virginia, April 1996. Int Psychogeriatr 8(Suppl 3):215-552.
7. APA. 1994. Diagnostic and statistical manual of mental disorders. 4th ed. (DSM-IV). American Psychiatric Press, Washington, D.C.
8. Bechara A. 2003. Risky business: emotion, decision-making, and addiction. J Gambl Stud 19:23-51.
9. Benito-Leon J, Morales JM, Rivera-Navarro J. 2002. Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol 9:497-502.
10. BGA-Kommission E. 1994. Monographie: Trockenextrakt (35-67:1) aus Ginkgo-biloba-Blättern, extrahiert mit Aceton-Wasser. Bundesanzeiger (Banz), No. 133, p. 7361.
11. Birks J, Grimley EV, Van Dongen M. 2002. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 4:CD003120.
12. 1A receptor desensitization: Protective effects of Ginkgo biloba extract (EGb 761). Fundam Clin Pharmacol 9:169-174.
13. Brochet D, Chermat R, DeFeudis FV, Drieu K. 1999. Effects of single intraperitoneal injections of an extract of Ginkgo biloba (EGb 761) and its terpene trilactone constituents on barbital-induced narcosis in the mouse. Gen Pharmacol 33:249-56.
14. Cala S, Crismon ML, Baumgartner J. 2003. A survey of herbal use in children with attention-deficit-hyperactivity disorder or depression. Pharmacotherapy 23:222-230.
15. Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF. 2001. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriat Psychiatry 16:1156-1162.
16. Chandrasekaran K, Liu L-I, Hatanpää K, Drieu K, Rapoport SI. 1998. Stimulation of mitochondrial gene expression by bilobalide, a component of Ginkgo biloba extract (EGb 761). In: Packer L, Christen Y, editors. Advances in Ginkgo biloba extract research, Vol. 7. Ginkgo biloba Extract (EGb 761): lessons from cell biology. Paris: Elsevier, p 121-128.
17. Chatterjee SS. 1985. Effects of Ginkgo biloba extract on cerebral metabolic processes. In: Agnoli A, Rapin JR, Scapagnini V, Weitbrecht WV, editors. Effects of Ginkgo biloba on organic cerebral impairment. London; John Libbey. p 5-14.
18. Chermat R, Brochet D, DeFeudis FV, Drieu K. 1997. Interactions of Ginkgo biloba extract (EGb 761), diazepam and ethyl beta-carboline-3-carboxylate on social behavior of the rat. Pharmacol Biochem Behav 56:333-339.
19. Christen Y. 2000. Oxidative stress and Alzheimer disease. Am J Clin Nutr 71:6215-6295.
20. Christen Y, Maixent JM. 2002. What is Ginkgo biloba extract EGb 761? An overview: from molecular biology to clinical medicine. Cell Mol Biol (Noisy-le-grand) 48:601-611.
21. Cieza A, Maier P, Poppel E. 2003. The effect of Ginkgo biloba on healthy elderly subjects. Fortschr Med Orig 121:5-10 [in German].
22. A receptors. Ann NY Acad Sci 585:231-240.
23. DeFeudis, FV. 1991. Ginkgo biloba extract (EGb 761): pharmacological activities and clinical applications. Paris: Elsevier. 187 pp.
24. DeFeudis FV. 1998. Ginkgo biloba extract (EGb 761): from chemistry to the clinic. Wiesbaden: Ullstein-Mosby, 401 pp.
25. DeFeudis FV. 2002. Effects of Ginkgo biloba extract (EGb 761) on gene expression: possible relevance to neurological disorders and age-associated cognitive impairment. Drug Dev Res 57:214-235.
26. DeFeudis FV, Drieu K. 2000. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets 1:25-58.
27. DeFeudis FV, Auguet M, Delaflotte S, Hellegouarch A, Baranes J, Chapelat M, Braquet M, Etienne A, Drieu K, Clostre F, Braquet P. 1985. Some in vitro and in vivo actions of an extract of Ginkgo biloba (GB 761). In: Agnoli A, Rapin JR, Scapagnini V, Weitbrecht WV, editors. Effects of Ginkgo biloba on organic cerebral impairment. London: John Libbey. p 17-29.
28. Eckmann F, Schlag H. 1982. Kontrollierte Doppelblind-Studie zum Wirksamkeitsnachweis von Tebonin forte bei Patienten mit zerebrovaskulärer Insuffizienz. Fortschr Med 100:1474-1478.
29. Edell WS, Tunis SL. 2001. Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients. Am J Geriatr Psychiat 9:289-297.
30. Ernst E, Pittler MH. 1999. Ginkgo biloba and dementia: a systematic review of double-blind, placebo-controlled trials. Clin Drug Invest 17:301-308.
31. Farrin L, Hull L, Unwin C, Wykes T, David A. 2003. Effects of depressed mood on objective and subjective measures of attention. J Neuropsychiat Clin Neurosci 15:98-104.
32. Ferrante RJ, Klein AM, Dedeoglu A, Beal MF. 2001. Therapeutic efficacy of EGb 761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis. J Mol Neurosci 17:89-96.
33. Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. 1996. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 8(Suppl 3): 497-500.
34. Fowler JS, Wang GJ, Volkow ND, Logan J, Franceschi D, Franceschi M, MacGregor R, Shea C, Garza V, Liu N, Ding YS. 2000. Evidence that Ginkgo biloba extract does not inhibit MAO A and B in living human brain. Life Sci 66:PL141-146.
35. Gessner B, Voelp A, Klasser M. 1985. Study of the long-term action of a Ginkgo biloba extract on vigilance and mental performance as determined by means of quantitative pharmaco-EEG and psychometric measurements. Arzneimittelforschung 35:1459-1465.
36. Gold PE, Cahill L, Wenk GL. 2003. The lowdown on Ginkgo biloba. Sci Am 288:86-91.
37. Greenhill L. 1992. Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiat Clin N Am 15:1-27.
38. Gregg AR. 2003. Mouse models and the role of nitric oxide in reproduction. Curr Pharm Des 9:391-398.
39. Grossberg GT. The ABC of Alzheimer's disease: behavioral symptoms and their treatment. Int Psychogeriatr 14(Suppl 1):27-49.
40. Halama P. 1990. What does the special extract do (EGb 761)? Treatment with Ginkgo biloba in patients with cerebral insufficiency and refractory depressive symptoms: results of a placebo-controlled, randomized double-blind pilot study. Therapiewoche 40:3760-3765.
41. Halama P, Bartsch G, Meng G. 1988. Hirnleistungsstörungen vaskulärer Genese. Randomisierte Doppelblindstudie zur Wirksamkeit von Ginkgo-biloba-Extrakt. Fortschr Med 106:408-412.
42. Hemels ME, Lanctjt KL, Iskedjian M, Einarson TR. 2001. Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia. Drugs Aging 18:527-550.
43. Herrmann N. 2001. Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci 28(Suppl 1):S96-S107.
44. Hoerr R. 2003. Behavioural and psychological symptoms of dementia (BPSD): effects of Egb 761. Pharmacopsychiatry 36(Suppl 1):S56-S61.
45. Hofferberth B. 1989. Einfluss von Ginkgo biloba-Extrakt auf neurophysiologische und psychometrische Messergebnisse bei Patienten mit hirnorganischem Psychosyndrom: Eine Doppel-blindstudie gegen Plazebo. Arzneimittelforschung 39:918-922.
46. Hofferberth B. 1994. The efficacy of EGh 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Human Psychopharmacol 9:215-222.
47. Huang SH, Duke RK, Chebib M, Sasaki K, Wada K, Johnston GA. 2003. Bilobalide, a sesquiterpene trilactone from Ginkgo biloba, is an antagonist at recombinant alpha(1)beta(2)gamma(2L) GABA(A) receptors. Eur J Pharmacol 464:1-8.
48. 1A receptors during ageing: reversal by Ginkgo biloba extract (EGb 761). J Pharm Pharmacol 46:316-318.
49. Imaizumi M, Onodera K. 2000. Animal models of "anxiety." Nippon Yakurigaku Zasshi 115:5-12 (in Japanese).
50. Israel L, Dell'Accio E, Martin G, Hugonot R. 1987. Extrait de Ginkgo biloba et exercices d'entrainement de la mémoire. Evaluation comparative chez des personnes agées ambulatoires. Psychol Med 19:1431-1439.
51. Itil T, Martorano D. 1995. Natural substances in psychiatry (Ginkgo biloba in dementia). Psychopharmacol Bull 31:147-158.
52. Itil TM, Erlap E, Tsambis E, Itil KZ, Stein U. 1996. Central nervous system effects of Ginkgo biloba, a plant extract. Am J Therapeut 3:63-73.
53. Janssens D, Michiels C, Delaive E, Eliaers F, Drieu K, Remacle J. 1995. Protection of hypoxia-induced ATP decrease in endothelial cells by Ginkgo biloba extract and bilobalide. Biochem Pharmacol 50:991-999.
54. Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R. 1996. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 29:47-56.
55. Kanter ED, Wilkinson CW, Radant AD, Petrie EC, Dobie DJ, McFall ME, Peskind ER, Raskind MA. 2001. Glucocorticoid feedback sensitivity and adrenocortical responsiveness in posttraumatic stress disorder. Biol Psychiat 50:238-245.
56. Kenney C, Norman M, Jacobson M, Lampinen S, Nguyen DP, Corey-Bloom J. 2002. A double-blind, placebo-controlled, modified crossover pilot study of the effects of Ginkgo biloba on cognitive and functional abilities in multiple sclerosis. Neurology 58(Suppl 3):A458-A459.
57. Kleijnen J, Knipschild P. 1992a. Ginkgo biloba. Lancet 340:1136-1139.
58. Kleijnen J, Knipschild P. 1992b. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 34:352-358.
59. Laks J, Engelhardt E, Marinho V, Rozenthal M, Souza FC, Bacaltchuk J, Stoppe A Jr, Ferreira RC, Bottino C, Scalco M. 2001. Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly. Arq Neuropsiquiatr 59:859-864.
60. Landgraf R, Wigger A, Holsboer F, Neumann ID. 1999. Hyperreactive hypothalamo-pituitary-adrenocortical axis in rats bred for high anxiety-related behaviour. J Neuroendocrinol 11:405-407.
61. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. 1997. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278:1327-1332.
62. Le Bars PL, Kieser M, Itil KZ. 2000. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord 11:230-237.
63. Letzel H, Haan J, Feil WB. 1996. Nootropics: efficacy and tolerability of products from three active substance classes. J Drug Dev Clin Pract 8:77-94.
64. Lupien SJ, de Leon M, de Santi S, Convit A, Turshish C, Nair NPV, Thakur M, McEwen BS, Hanger RL, Meaney MJ. 1998. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nature Neurosci 1:69-73.
65. Luthringer R, d'Arbigny P, Machler JP. 1995. Ginkgo biloba extract (EGb 761), EEG and event-related potentials mapping profile. In: Christen Y, Courtois Y, Droy-Lefaix MT, editors. Advances in Ginkgo biloba extract research, Vol. 4. Effects of Ginkgo biloba extract (EGb 761) on aging and age-related disorders. Paris: Elsevier, p 107-118.
66. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. 2002. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 288:1475-1483.
67. Lyon MR, Cline JC, Totosy de Zepetnek J, Shan JJ, Pang P, Benishin C. 2001. Effect of the herbal extract combination Panax quinquefolium and Ginkgo biloba on attention-deficit hyperactivity disorder: a pilot study. J Psychiatry Neurosci 26:221-228.
68. Mancini M, Agozzino B, Bompani R. 1993. Clinical and therapeutic effects of Ginkgo biloba extract (GBE) versus placebo in the treatment of psychorganic senile dementia of arteriosclerotic origin. Gazzetta Med Ital 152:69-80.
69. Manocha A, Pillai KK, Husain SZ. 1997. Effect of Ginkgo biloba on chemoshock in mice. Ind J Pharmacol 29:198-200.
70. Marcilhac A, Dakine N, Bourhim N, Guillaume V, Grino M, Drieu K, Oliver C. 1998. Effect of chronic administration of Ginkgo biloba extract or ginkgolide on the hypothalamic-pituitary-adrenal axis in the rat. Life Sci 62:2329-2340.
71. Martin RA. 2001. Humor, laughter, and physical health: methodological issues and research findings. Psychol Bull 127:504-519.
72. Mix JA, Crews WD Jr. 2002. A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol 17:267-277.
73. Moos WH, Davis RE, Schwarz RD, Gamzu ER. 1988. Cognition activators. Medicinal Res Rev 8:353-391.
74. Nöldner M, Chatterjee SS. 1994. Anxiolytic-like activity of bilobalide. Naunyn-Schmiedeberg's Arch Pharmacol 349(Suppl):R 97 (Abstr. no. 388).
75. O'Brien JT, Ames D, Schweitzer I. 1993. HPA axis function in depression and dementia: a review. Int J Geriat Psychiatry 8:887-898.
76. Oken BS, Storzbach DM, Kaye JA. 1998. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 55:1409-1415.
77. Oquendo MA, Echavarria G, Galfalvy HC, Grunebaum MF, Burke A, Barrera A, Cooper TB, Malone KM, John Mann J. 2003. Lower cortisol levels in depressed patients with comorbid post-traumatic stress disorder. Neuropsychopharmacology 28:591-598.
78. Orrell MW, O'Dwyer A-M. 1995. Dementia, ageing, and the stress control system. Lancet 345:666-667.
79. Overmier JB, Seligman ME. 1967. Effects of inescapable shock upon subsequent escape and avoidance responding. J Comp Physiol Psychol 63:28-33.
80. Paleacu D, Mazeh D, Mirecki I, Even M, Barak Y. 2002. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol 25:313-317.
81. Pardon MC, Lepicard E, Perez-Diaz F, Christen Y, Cohen-Salmon C. 1997. Chronic mild stress-induced dysregulation of decision-making in mice: regulatory effect of long-term treatment with Ginkgo biloba extract (EGb 761). In: Papadopoulos V, Drieu K, Christen Y, editors. Advances in Ginkgo biloba extract research, vol. 6. Adaptive effects of Ginkgo biloba extract. Paris: Elsevier. p 89-98.
82. Pardon MC, Joubert C, Perez-Diaz F, Christen Y, Launay JM, Cohen-Salmon C. 2000. In vivo regulation of cerebral monoamine oxidase activity in senescent controls and chronically stressed mice by long-term treatment with Ginkgo biloba extract (EGb 761). Mech Ageing Dev 113:157-168.
83. Pidoux B, Bastien C, Niddam S. 1983. Etude à double insu, face au placebo, des effets de l'extrait de Ginkgo biloba sur l'état clinique et l'EEG quantifiŕ. J Cerebr Blood Flow Metab 3(Suppl 1): 5556-5557.
84. Pietri S, Maurelli E, Drieu K, Culcasi M. 1997. Cardioprotective and antioxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol 29:733-742.
85. Pincemail J, Dupuis M, Nasr C, Hans P, Haag-Berrurier M, Anton R, Deby C. 1989. Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract. Experientia 45:708-712.
86. Porsolt RD, Martin P, Lenègre A, Fromage S, Drieu K. 1990. Effects of an extract of Ginkgo biloba (EGb 761) on "learned helplessness" and other models of stress in rodents. Pharmacol Biochem Behav 36:963-971.
87. Porsolt RD, Roux S, Drieu K. 2000. Evaluation of a Ginkgo biloba extract (EGb 761) in functional tests for monoamine oxidase inhibition. Arzneimittelforschung 50:232-235.
88. Rai GS, Shovlin C, Wesnes KA. 1991. A double-blind, placebo controlled study of Ginkgo biloba extract (Tanakan) in elderly outpatients with mild to moderate memory impairment. Curr Med Res Opin 12:350-355.
89. Rapin JR, Lamproglon I, Drieu K, DeFeudis FV. 1994. Demonstration of the "anti-stress" activity of an extract of Ginkgo biloba (EGb 761) using a discrimination learning task. Gen Pharmacol 25:1009-1016.
90. Rapin JR, Provost P, Drieu K. 1997. Ginkgo biloba extract (EGb 761) anti-stress effects on hippocampal glucocorticoid receptors: Comparison with diazepam. In: Papadopoulos V, Drieu K, Christen Y, editors. Advances in Ginkgo biloba extract research, vol. 6. Adaptive effects of Ginkgo biloba extract. Paris: Elsevier. p 129-138.
91. Robert P. 2002. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. Curr Med Res Opin 18:156-171.
92. Rodgers RJ. 1997. Animal models of "anxiety": where next? Behav Pharmacol 8:477-496.
93. Rosler M. 2002. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl 127:20-36.
94. Saletu B, Grunberger J. 1985. Memory dysfunction and vigilance: neurophysiological and psychopharmacological aspects. Ann NY Acad Sci 444:406-427.
95. Sapolsky RM. 1996. Why stress is bad for your brain. Science 273:749-750.
96. Schubert H, Halama P. 1993. Primary therapy-resistant depressive instability in elderly patients with cerebral disorders: efficacy of a combination of Ginkgo biloba extract EGb 761 with antidepressants. Geriatr Forsch 1:45-53.
97. Seaward BL. 1992. Humor's healing potential. Health Prog 73:66-70.
98. Shih JC, Chen K, Ridd MJ, Seif I. 2000. Ginkgo biloba abolishes aggression in mice lacking MAO A. Antioxid Redox Signal 2:467-471.
99. Sloley BD, Urichuk LJ, Morley P, Durkin J, Shan JJ, Pang PK, Coutts RT. 2000. Identification of kaempferol as a monoamine oxidase inhibitor and potential neuroprotectant in extracts of Ginkgo biloba leaves. J Pharm Pharmacol 52:451-459.
100. Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R. 2002. Ginkgo for memory enhancement: a randomized controlled trial. JAMA 288:835-840.
101. Solomon PR, DeVeaux R. 2003. Ginkgo and memory. JAMA 289:547-548.
102. Soulie C, Nicole A, Christen Y, Ceballos-Picot I. 2002. The Ginkgo biloba extract EGb 761 increases viability of hnt human neurons in culture and affects the expression of genes implicated in the stress response. Cell Mol Biol (Noisy-le-grand) 48:641-646.
103. Stocksmeier U, Eberlein M. 1992. Depressive Verstimmung bei Hirnleistungsstörungen, Wirkung cines Ginkgo-biloba-Extraktes in Doppelblindstudie überprüft. TW Neurol Psychiatrie 6:74-76.
104. Stoppe G, Staedt J. 1999. Psychopharmacotherapy of behavioral disorders in patients with dementia. Z Gerontol Geriatr 32:153-158 [in German].
105. Taillandier J, Ammar A, Rabourdin JP, Ribeyre JP, Pichon J, Niddam S, Pierart H. 1986. Traitement des troubles du vieillissement céré bral par l'extrait de Ginkgo biloba. Etude longitudinale multicentrique à double insu face au placebo. Presse Med 15:1583-1587.
106. Tendi EA, Bosetti F, Dasgupta SF, Stella AM, Drieu K, Rapoport SI. 2002. Ginkgo biloba extracts EGb 761 and bilobalide increase NADH dehydrogenase mRNA level and mitochondrial respiratory control ratio in PC12 cells. Neurochem Res 27:319-323.
107. Trovero F, Brochet D, Tassin JP, Drieu K. 1999. Ginkgo biloba extract EGb 761 reduces the development of amphetamine-induced behavioral sensitization: effects on hippocampal type II corticosteroid receptors. Brain Res 818:135-139.
108. van Dongen M, van Rossum E, Kessels A, Sielhorst H, Knipschild P. 2003. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol 56:367-376.
109. VIDAL. 1995. 71st ed. Paris: Editions du Vidal. p 1444-1445.
110. Vorberg G. 1985. GBE: long term study concerning the major symptoms of age-related cerebral disorders. Clin Trials J 22:149-157.
111. Weiss JM, Glazer HI. 1975. Effects of acute exposure to stressors on subsequent avoidance-escape behavior. Psychosom Med 37:499-521.
112. Weiss JM, Glazer HI, Pohorecky LA, Brick J, Miller NE. 1975. Effects of chronic exposure to stressors on avoidance-escape behavior and on brain norepinephrine. Psychosom Med 37:522-534.
113. Weitbrecht WV, Jansen W. 1986. Primär degenerative Demenz: Therapie mit GBE. Plazebokontrollierte Doppelblind-und Vergleichsstudie. Fortschr Med 104:199-202.
114. Wesnes K, Simmons D, Rook M, Simpson P. 1987. A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly. Human Psychopharmacol 2:159-169.
115. White HL, Scates PW, Cooper BR. 1996. Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci 58:1315-1321.
116. WHO (World Health Organization). 1999. WHO monographs on selected medicinal plants, Vol. 1. Geneva: World Health Organization.
117. Wilken JA, Berkowitz R, Kane R. 2002. Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 89:372-380.
118. Wolraich M, Hannah J, Pinnock T, Baumgaertel A, Brown J. 1996. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry 35:319-324.
119. Yehuda R. 2001. Biology of posttraumatic stress disorder. J Clin Psychiatry 62(Suppl 17):41-46.
120. Zaudig M. 2000. A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia. Drug Saf 23:183-195.
121. Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY. 2001. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry 62:878-883.
122. Zhou D, Zhang X, Su J, Nan Z, Cui Y, Liu J, Guan Z, Zhang P, Shen Y. 1999. The effects of classic antipsychotic haloperidol plus the extract of Ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia. Chin Med J (Engl) 112:1093-1096.